Adjuvant Therapy for High-Risk Intrahepatic Cholangiocarcinoma: A Real-World Study

This multicenter real-world study assesses the efficacy and safety of adjuvant therapies in postoperative intrahepatic cholangiocarcinoma (ICC) patients with high-risk recurrence factors. 90 eligible patients will be assigned to: Cohort 1: GP (gemcitabine/cisplatin) + adebrelimab Cohort 2: Apatinib + adebrelimab Cohort 3: S-1 (tegafur/gimeracil/oteracil) + adebrelimab Outcomes will be compared against historical real-world controls receiving standard chemotherapy.

NCT Number	NCT07640048
Lead Sponsor	Peking Union Medical College Hospital
Conditions	Intrahepatic Cholangiocarcinoma (Icc)
Enrollment	90 participants
Start Date	2025-05-04
Primary Completion	2028-12-31 (estimated)
Study Completion	2029-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-10